Targeted Therapy

Ongoing clinical trials at academic centers around the country are testing a new strategy of matching available targeted therapies to molecular abnormalities in tumors instead of treating the cancer site.

Chicago, IL—It is not a surprise that targeted therapies are the main drivers of spending on anticancer drugs in the United States. At the 2015 American Society of Clinical Oncology meeting, researchers presented data from several major cancer centers about the cost of targeted therapies.